WO2005039550A3 - Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds - Google Patents
Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds Download PDFInfo
- Publication number
- WO2005039550A3 WO2005039550A3 PCT/EP2004/052639 EP2004052639W WO2005039550A3 WO 2005039550 A3 WO2005039550 A3 WO 2005039550A3 EP 2004052639 W EP2004052639 W EP 2004052639W WO 2005039550 A3 WO2005039550 A3 WO 2005039550A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- prophylaxis
- treatment
- juvenile
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0415851-2A BRPI0415851A (en) | 2003-10-24 | 2004-10-22 | medical uses of compounds exhibiting cb1 antagonistic activity and combination treatment involving said compounds |
MXPA06004434A MXPA06004434A (en) | 2003-10-24 | 2004-10-22 | Novel medical uses of compounds showing cb1. |
JP2006536096A JP2007513872A (en) | 2003-10-24 | 2004-10-22 | Novel medical uses of compounds exhibiting CB1 antagonism and combination therapy with said compounds |
CA002543338A CA2543338A1 (en) | 2003-10-24 | 2004-10-22 | Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds |
AU2004283056A AU2004283056A1 (en) | 2003-10-24 | 2004-10-22 | Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds |
EP04817279A EP1753413A2 (en) | 2003-10-24 | 2004-10-22 | Novel medical uses of compounds showing cb sb 1/sb -antagonistic activity and combination treatment involving said compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03103961 | 2003-10-24 | ||
EP03103961.3 | 2003-10-24 | ||
EP03103967.0 | 2003-10-27 | ||
EP03103967 | 2003-10-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005039550A2 WO2005039550A2 (en) | 2005-05-06 |
WO2005039550A3 true WO2005039550A3 (en) | 2007-03-22 |
Family
ID=34524748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/052639 WO2005039550A2 (en) | 2003-10-24 | 2004-10-22 | Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1753413A2 (en) |
JP (1) | JP2007513872A (en) |
AU (1) | AU2004283056A1 (en) |
BR (1) | BRPI0415851A (en) |
CA (1) | CA2543338A1 (en) |
MX (1) | MXPA06004434A (en) |
RU (1) | RU2006117627A (en) |
WO (1) | WO2005039550A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1575901B1 (en) | 2002-12-19 | 2012-10-10 | Merck Sharp & Dohme Corp. | Substituted amides |
AR046132A1 (en) * | 2003-10-24 | 2005-11-23 | Solvay Pharm Gmbh | PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE COMPOUND WITH RECEIVER ACTIVITY OF CB1, OR A PROFARMACO, TAUTOMERO OR SALT OF THE SAME, AS A SUITABLE ACTIVE COMPONENT FOR THE TREATMENT AND / OR PROFILAXIS OF DISEASES RELATED TO THE RECEIVER CB1 IN PATIENTS OR YOUTH PATIENTS THE TREATMENT |
AR051202A1 (en) | 2004-09-20 | 2006-12-27 | Xenon Pharmaceuticals Inc | HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA |
US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
AU2005329423A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
CN101083994A (en) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | Heterocyclic derivatives and their use as therapeutic agents |
MX2007003321A (en) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents. |
CA2580845A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
WO2006034315A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
BRPI0611187A2 (en) | 2005-06-03 | 2010-08-24 | Xenon Pharmaceuticals Inc | amino thiazide derivatives as inhibitors of human stearoyl coa desaturase |
EP1921073A1 (en) | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,4-Triazole derivatives as sigma receptor inhibitors |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0377457A1 (en) * | 1989-01-05 | 1990-07-11 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole compounds, processes for the preparation thereof, and pharmaceutical composition comprising the same |
WO1996003388A1 (en) * | 1994-07-28 | 1996-02-08 | G.D. Searle & Co. | 1,2-substituted imidazolyl compounds for the treatment of inflammation |
WO1996003392A1 (en) * | 1994-07-27 | 1996-02-08 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
WO2000069848A1 (en) * | 1999-05-14 | 2000-11-23 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
WO2002076949A1 (en) * | 2001-03-22 | 2002-10-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
WO2003027076A2 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity |
WO2003026647A1 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
WO2003026648A1 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
WO2003040107A1 (en) * | 2001-09-24 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity |
WO2003039451A2 (en) * | 2001-11-08 | 2003-05-15 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole pyridazinones as adenosine antagonists |
WO2003043619A1 (en) * | 2001-11-23 | 2003-05-30 | Astrazeneca Ab | New use for the treatment of gastroesophageal reflux disease |
WO2003063781A2 (en) * | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
WO2003078413A1 (en) * | 2002-03-18 | 2003-09-25 | Solvay Pharmaceuticals B.V. | Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity |
WO2004012727A1 (en) * | 2002-08-06 | 2004-02-12 | Abbott Laboratories | Compositions comprising polysaturated fatty acid (pufas) for the control of appetite and body weight management |
WO2004026301A1 (en) * | 2002-09-19 | 2004-04-01 | Solvay Pharmaceuticals B.V. | 1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
WO2004058255A1 (en) * | 2002-12-24 | 2004-07-15 | Astrazeneca Ab | 4, 5-diarylthiazole derivatives as cb-1 ligands |
-
2004
- 2004-10-22 MX MXPA06004434A patent/MXPA06004434A/en not_active Application Discontinuation
- 2004-10-22 BR BRPI0415851-2A patent/BRPI0415851A/en not_active IP Right Cessation
- 2004-10-22 AU AU2004283056A patent/AU2004283056A1/en not_active Abandoned
- 2004-10-22 CA CA002543338A patent/CA2543338A1/en not_active Abandoned
- 2004-10-22 EP EP04817279A patent/EP1753413A2/en not_active Withdrawn
- 2004-10-22 JP JP2006536096A patent/JP2007513872A/en not_active Withdrawn
- 2004-10-22 RU RU2006117627/04A patent/RU2006117627A/en not_active Application Discontinuation
- 2004-10-22 WO PCT/EP2004/052639 patent/WO2005039550A2/en active Application Filing
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0377457A1 (en) * | 1989-01-05 | 1990-07-11 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole compounds, processes for the preparation thereof, and pharmaceutical composition comprising the same |
WO1996003392A1 (en) * | 1994-07-27 | 1996-02-08 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
WO1996003388A1 (en) * | 1994-07-28 | 1996-02-08 | G.D. Searle & Co. | 1,2-substituted imidazolyl compounds for the treatment of inflammation |
WO2000069848A1 (en) * | 1999-05-14 | 2000-11-23 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
WO2002076949A1 (en) * | 2001-03-22 | 2002-10-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
WO2003027076A2 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity |
WO2003026647A1 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
WO2003026648A1 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
WO2003040107A1 (en) * | 2001-09-24 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity |
WO2003039451A2 (en) * | 2001-11-08 | 2003-05-15 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole pyridazinones as adenosine antagonists |
WO2003043619A1 (en) * | 2001-11-23 | 2003-05-30 | Astrazeneca Ab | New use for the treatment of gastroesophageal reflux disease |
WO2003063781A2 (en) * | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
WO2003078413A1 (en) * | 2002-03-18 | 2003-09-25 | Solvay Pharmaceuticals B.V. | Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity |
WO2004012727A1 (en) * | 2002-08-06 | 2004-02-12 | Abbott Laboratories | Compositions comprising polysaturated fatty acid (pufas) for the control of appetite and body weight management |
WO2004026301A1 (en) * | 2002-09-19 | 2004-04-01 | Solvay Pharmaceuticals B.V. | 1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
WO2004058255A1 (en) * | 2002-12-24 | 2004-07-15 | Astrazeneca Ab | 4, 5-diarylthiazole derivatives as cb-1 ligands |
Non-Patent Citations (8)
Title |
---|
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2001, GERDEMAN G L ET AL: "CB1 cannabinoid receptors are critical for induction of striatal long term depression", XP002271460, Database accession no. PREV200100520232 * |
DYCK, BRIAN ET AL: "Potent imidazole and triazole CB1 receptor antagonists related to SR141716", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 14(5), 1151-1154 CODEN: BMCLE8; ISSN: 0960-894X, 2004, XP001197288 * |
HASSAN, HODA Y. ET AL: "Design and synthesis of some new 1H-1,2,4-triazoles of potential antiinflammatory and analgesic activities", BULLETIN OF PHARMACEUTICAL SCIENCES, ASSIUT UNIVERSITY , 17(1), 27-39 CODEN: BPAUEC, 1994, XP008033363 * |
JAGEROVIC N ET AL: "A NOVEL CLASS OF HETEROCYCLIC CANNABINOIDS: DESIGN, PREPARATION, IN VITRO AND IN VIVO STUDIES OF 1,2,4-TRIAZOLES", DRUGS OF THE FUTURE, BARCELONA, ES, vol. 27, no. SUPPL A, 1 September 2002 (2002-09-01), pages 284, XP001121041, ISSN: 0377-8282 * |
M. H. BEERS AND R. BERKOW: "The Merck Manual of Diagnosis and Therapy, Seventeenth Edition", 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, N.J., XP002271459 * |
OCHI TAKEHIRO ET AL: "The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 391, no. 1-2, 10 March 2000 (2000-03-10), pages 49 - 54, XP001197357, ISSN: 0014-2999 * |
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, 2001, 31st Annual Meeting of the Society for Neuroscience;San Diego, California, USA; November 10-15, 2001, pages 1024, ISSN: 0190-5295 * |
TANAKA A ET AL: "Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2 substituted- thiazoles", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, no. 8, 15 April 1994 (1994-04-15), pages 1189 - 1199, XP002268971, ISSN: 0022-2623 * |
Also Published As
Publication number | Publication date |
---|---|
AU2004283056A1 (en) | 2005-05-06 |
RU2006117627A (en) | 2007-12-10 |
WO2005039550A2 (en) | 2005-05-06 |
MXPA06004434A (en) | 2006-06-20 |
BRPI0415851A (en) | 2007-01-02 |
JP2007513872A (en) | 2007-05-31 |
EP1753413A2 (en) | 2007-02-21 |
CA2543338A1 (en) | 2005-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006067445A3 (en) | Csf-1r kinase inhibitors | |
WO2003040107A8 (en) | Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity | |
WO2006070195A8 (en) | Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases | |
MXPA02011079A (en) | Heterocyclic inhibitors of glycogen synthase kinase gsk 3. | |
WO2005121097A3 (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
EP1633722A4 (en) | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | |
WO2006059234A3 (en) | Bicyclic amides as kinase inhibitors | |
WO2003024965A3 (en) | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv | |
WO2005044192A3 (en) | Triazole compounds and uses related thereto | |
WO2002076976A3 (en) | Rho-kinase inhibitors | |
WO2002076977A3 (en) | Rho-kinase inhibitors | |
WO2006099541A3 (en) | Therapeutic wound care product | |
WO2006067428A3 (en) | 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands | |
SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
MX2008013836A (en) | 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
WO2005075425A3 (en) | Substituted bisarylurea derivatives as kinase inhibitors | |
WO2005080343A3 (en) | 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators | |
GB0222495D0 (en) | Compounds | |
WO2005039550A3 (en) | Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds | |
MX2009005174A (en) | 5-sulfanylmethyl-[1,2,4] triazol[1, 5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists. | |
WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
WO2007009721A3 (en) | Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments | |
PL374443A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
EP1398029A8 (en) | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480030116.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004817279 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2543338 Country of ref document: CA Ref document number: 2004283056 Country of ref document: AU Ref document number: PA/a/2006/004434 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006536096 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2004283056 Country of ref document: AU Date of ref document: 20041022 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004283056 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006117627 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0415851 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004817279 Country of ref document: EP |